TICKERNERD
Menu
CELUCELUHealthcare · Biotechnology

CELU Stock Forecast: Celularity, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$1.71
+6.87% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 3 Oct 2026 — in the lower half.

Market cap
$55.5M
Ticker Nerd rank
30 / 100
Median analyst target
—
Analysts covering
0
Revenue$4.1M−77.4% y/y
Operating income−$22.1M
Net income−$24.4M
Free cash flow−$5.1M
Quarterly, 8 quarters to 31 Dec 2025 · latest quarter's figure shown
Total return, dividends reinvested
1W
+22.1%
1M
+1.8%
YTD
+54.1%
1Y
−19.7%
From 52W high
−24.7%
From 52W low
+186.0%
$0.60
$2.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CELU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Celularity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
98
Size
81
Issuance
51
Momentum
46
Quality
37
Revisions
25
Value
18
Growth
17
Volatility
9

Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (9): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CELU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CELU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26CELU

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Of the 14 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
9 Sept 2025WBB SecuritiesUpgradeBuy—
9 Sept 2025WBB SecuritiesUpgradeBuy$6.00
18 Aug 2025WBB SecuritiesInitiatesSpeculative Buy—
30 Jan 2023HC Wainwright & Co.MaintainsBuy$15 → $2.50
30 Jan 2023Morgan StanleyDowngradeUnderweight$5.00 → $1.00
22 Dec 2022OppenheimerDowngradePerform—
12 Sept 2022Morgan StanleyMaintainsEqual-Weight$8.00 → $5.00
25 Aug 2022Alliance Global PartnersInitiatesBuy$15
23 Aug 2022Truist SecuritiesMaintainsHold$10 → $6.00
22 June 2022HC Wainwright & Co.InitiatesBuy—
6 Apr 2022Truist SecuritiesDowngradeHold—
28 Jan 2022OppenheimerInitiatesOutperform—
24 Nov 2021Morgan StanleyInitiatesEqual-Weight—
19 Oct 2021Truist SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CELU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Celularity, Inc. returned −19.7% against +17.0% for the S&P 500, dividends included.

CELU vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26CELUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CELU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Celularity, Inc. (CELU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.3×

Cheaper than 69% of US stocks

Price / sales
2.9×

Cheaper than 44% of US stocks

Price / book
—
EV / EBITDA
−2.3×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
−66.3%

Higher than 4% of US stocks

Earnings growth (YoY)
−77.4%

Higher than 5% of US stocks

Gross margin
−79.7%

Higher than 2% of US stocks

Operating margin
−263.5%

Higher than 10% of US stocks

Net margin
24.4%

Higher than 85% of US stocks

Returns & dividend
Return on equity
241.2%

Higher than 99% of US stocks

Return on assets
−32.3%

Higher than 13% of US stocks

Dividend yield
0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Celularity, Inc. (CELU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Celularity, Inc. has a market value of $55.5M and an enterprise value of $123.2M.

  • Revenue in the twelve months to 31 Dec 2025: $26.6M. The latest quarter shrank 66.3% year on year.

  • Net income over the same four quarters: −$91.7M, a −345.4% net margin.

  • Free cash flow in the twelve months to 31 Dec 2025: −$13.3M, after $0.0 of capital spending.

  • Shares outstanding: 28.8M.

  • Trailing P/E: 2.3×; forward P/E: −3.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Celularity, Inc. employs 115 people — $231K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2025 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

CELU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CELUCelularity, Inc.$55.5M
30
EDSAEdesa Biotech, Inc.$52.2M
50
INMBINmune Bio, Inc.$51.3M
53
ELTXElicio Therapeutics, Inc.$50.5M
38
EXOZeXoZymes, Inc.$53.6M
13
ANVSAnnovis Bio, Inc.$50.2M
27
SERSerina Therapeutics, Inc.$49.8M
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Celularity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CELU news & analysis

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner

GlobeNewsWire · 30 Sept 2026positive

Celularity highlighted the anticipated Q1 2027 opening of Fontaine Vitale in Bali, which it expects to create potential new revenue opportunities in the Asia-Pacific regenerative medicine market. The company positioned this strategic partner facility as a milestone in its regional expansion.

Why it matters — A CELU watcher would care because the planned opening signals potential new revenue streams and an expanded footprint in the Asia-Pacific regenerative medicine market.

Celularity Announces Naveen Jain to Join Board of Directors

GlobeNewsWire · 29 Sept 2026neutral

Celularity announced that Naveen Jain, founder and CEO of Viome Life Sciences Inc., will join its Board of Directors. The announcement was made via press release on September 29, 2026.

Why it matters — A CELU watcher would care because adding a prominent biotech founder to the board could bring new expertise and perspective to the company's governance.

Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements

GlobeNewsWire · 24 Sept 2026positive

Celularity announced the closing of over $10 million in initial financing as part of a recapitalization of up to $28 million, intended to accelerate growth following significant operating improvements. The company is targeting positive operating cash flow by Q1 2027.

Why it matters — This initial financing closing provides additional capital to support Celularity's growth plans and its stated objective of reaching positive operating cash flow by Q1 2027.

Celularity Provides Update Regarding Nasdaq Listing Compliance

GlobeNewsWire · 25 Aug 2026negative

Celularity announced that on August 21, 2026, it received a notification from Nasdaq stating the company is not in compliance with Listing Rule 5250(c)(1) because it has not filed its quarterly report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Form 10-Q for the period ended March 31, 2026.

Why it matters — Delinquent filing of required periodic financial reports puts Celularity's Nasdaq listing compliance at risk, which is a significant concern for shareholders monitoring the company's regulatory standing.

FAQ

Frequently asked questions about CELU stock

How does Ticker Nerd's model rank CELU?

As at 3 Oct 2026, Celularity, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).

What is the CELU stock forecast for 2030?

No analyst covering Celularity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELU are extrapolating price history, which says nothing about the business.

How has CELU stock performed over the past year?

Celularity, Inc. returned -19.7% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Celularity, Inc. do?

Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products.

What is the latest news on CELU?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner". Celularity highlighted the anticipated Q1 2027 opening of Fontaine Vitale in Bali, which it expects to create potential new revenue opportunities in the Asia-Pacific regenerative medicine market. The company positioned this strategic partner facility as a milestone in its regional expansion.

Company

About Celularity, Inc.

Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products. Celularity’s current business centers on three operating segments: Cell Therapy, Degenerative Disease, and BioBanking. The Cell Therapy segment develops off-the-shelf, cryopreserved allogeneic cell therapies, including programs based on mesenchymal-like adherent stromal cells, natural killer cells, and engineered T-cells for oncology, immune, infectious, and age-related diseases. The Degenerative Disease segment supports products used in surgical and wound care markets, while BioBanking provides storage services for stem cells from umbilical cords and placentas. Headquartered in Florham Park, New Jersey, Celularity occupies a niche within biotechnology that combines regenerative medicine research with commercial biobanking and biomaterials services.

CEO Dr. Robert Joseph Hariri M.D., Ph.D. · 115 employees · United States · https://www.celularity.com